Research
Hormonal
Inflammation indirectly causes muscle atrophy by dysregulating the Hypothalamic-Pituitary-Adrenal (HPA) axis, leading to excessive glucocorticoid release, which further inhibits muscle protein synthesis and promotes proteolysis.
Managing stress and underlying inflammation is crucial because chronic stress and inflammation can trigger hormonal responses (cortisol) that actively break down muscle. Medical interventions that stabilize the HPA axis or reduce inflammatory cytokines may help preserve muscle mass.
GoodSupportsHIGH confidence
Systemic inflammatory mediators indirectly lead to muscle mass loss through dysregulation of tissues and organ systems... Pro-inflammatory cytokines such as IL-1 and IL-6 can play a role in all parts of the HPA axis to increase the secretion of adrenocorticotropic hormone (ACTH)... resulting in excessive steroids in the bloodstream, and eventually triggering muscle atrophy.
Why this rating
Supported by multiple references to in vivo studies and established endocrine physiology.
Source
Inflammation: Roles in Skeletal Muscle Atrophy
Yanan Ji et al. · Antioxidants · 2022
DOI 10.3390/antiox11091686
narrative_reviewCited 274×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Chronic systemic inflammation drives skeletal muscle atrophy by directly activating pro-catabolic signaling pathways (NF-κB, JAK/STAT, p38MAPK) that increase protein degradation via UPS/ALP and inhibit protein synthesis via IGF-1/Akt/mTOR suppression.Good
- Myostatin (MSTN) levels are increased by inflammatory factors (TNF-α, IL-6) and act as a negative regulator of muscle mass by activating the Smad2/3 pathway, which upregulates E3 ubiquitin ligases (MuRF1, Atrogin-1) and inhibits satellite cell recruitment.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →